Cardio Diagnostics Holdings Launches Revolutionary Blood Test for Early Detection of Coronary Heart Disease

Tuesday, February 28, 2023

A combined epigenetic-genetic blood test for the early detection of coronary heart disease, PrecisionCHD™, has been launched by Cardio Diagnostics Holdings.

The second clinical test created by Cardio Diagnostics' in-house AI-driven Combined Epigenetic-Genetic Engine is the PrecisionCHD.

PrecisionCHD uses genetic (single nucleotide polymorphism) and epigenetic (DNA methylation) biomarkers as well as a proprietary machine-learning model developed by analyzing billions of genomic and epigenomic data points to detect coronary heart disease with better than 75% sensitivity in both men and women.

The Actionable Clinical Intelligence tool that comes with PrecisionCHD maps a patient's individual biomarker profile onto modifiable risk factors like smoking, diabetes, hypertension, and hypercholesterolemia, which are considered to be major drivers to coronary heart disease.

The non-invasive, simple test gives medical professionals an alternative to conventional CHD diagnostic methods and offers a detailed, personalized patient report on the state of their CHD.

Harvard Medical School - Leadership in Medicine Southeast Asia47th IHF World Hospital CongressHealthcare CNO SummitHealthcare CMO Summit